NCT04367090: Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor, Chemotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patients who have received more than 1 line of chemotherapy or immunotherapy; Patients with a history of HER2 targeting tyrosine kinase inhibitors (e.g. Tukysa/tucatinib, Nerlynx/neratinib, Tykerb/lapatinib) or monoclonal antibodies (e.g. Enhertu/trastuzumab deruxtecan, Kadcyla/trastuzumab emtansine/T-DM1) except for Herceptin/trastuzumab or Perjeta/pertuzumab

Comments are closed.

Up ↑